---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-24-000070"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:22:24.371760+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma to acquire Alimera Sciences for $5.50/share + CVR, funded by $280M debt

## Summary
- Deal consideration: $5.50 cash plus one CVR per Alimera share; adds ~$105M in branded revenue to ANI's rare disease segment.
- CVR pays up to $0.25 per milestone: $0.25 if 2026 net revenue > $140M, $0.25 if 2027 net revenue > $160M.
- Financing: $280M committed debt from JPMorgan and Blackstone; deal expected to close by Dec 21, 2024.
- Accretion: high single to low double digit adj. non-GAAP EPS accretion in 2025; $35-38M adj. EBITDA incl. $10M cost synergies.
- Caligan Partners (~32.1% holder) agreed to vote in favor; termination fee $10.4M under certain conditions.

## SEC filing metadata
- accession: 0001023024-24-000070
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000070/0001023024-24-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000070/ani-20240621.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-24-000070
- JSON: https://secwatch.observer/filing/0001023024-24-000070.json
- Plain text: https://secwatch.observer/filing/0001023024-24-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.